TMH: 6 82/05/04 20395-64908 1-001-01/0


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	6395-64908
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1642 1648
Examiner Name	Jeffrey S. Parkin

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS							
8		Chang et al., "Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus," Virology, 306:170-180, 2003.							
1		Chang et al., "Flavivirus DNA Vaccines," Annals New York Academy of Sciences, 272-285							
		Davis et al., "West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays," J. Virology, 75(9):4040-4047, May 2001							
•		Hunt et al., "A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen," J. Virological Methods, 97:133-149, 2001							
		,							
,									

EXAMINER SIGNATURE:	DATE CONSIDERED: N (12 /04

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-64908-01
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1648
Examiner Name	Jeffrey S. Parkin

U.S. PATENT DOCUMENTS

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee					
7		6,258,788	07/10/2001	Schmaljohn					
•			OTHER RE	EFERENCES					
9		Chang et al., "Recen Vaccines 3(2):199-22		irus vaccine development" Expert Rev.					
1	_	Guirakhoo et al., "Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates" J. Virol. 74(12):5477-5485, 20							
-		Simmons et al., "Sho	ort Report: Antibody Re Recombinant Protein Su	esponses of Mice Immunized with a abunit Vaccine" Am. J. Trop. Med. Hyg.					

(
EXAMINER SIGNATURE:		DATE CONSIDERED: N 12	04
	_		

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		-			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/826,115 April 4, 2001 Chang		
		Filing Date			
		First Named Inventor			
	·	Art Unit	1642 1648		
		Examiner Name	Not yet known		
NC	Monath, "Flaviviouses," Virology (R.N. Fields,	ed.) 763-814, 1990			
	Pincus et al., "Recombinant vaccinia virus proclethal yellow fever encephalitis," Virology 187:	ducing the prM and E proteins of ye	Tow fever virus protects mice from		
	Ramelow et al., "Detection of tick-borne encep reaction," J. Virological Methods 45:115-119,	ohalitie virus RNA in ticks (Isodes r	icinus) by the polymerase chain		
	Schalich et al., "Recombinant subviral particles		are fusogenic and provide a model		

Attorney Docket Number | 6395-64908

* Reference were met considered. IDS failst comply with 37 CFR 1.98.

system for studying flavivirus envelope glycoprotein functions," J. Virol. 70(7):4549-4557, 1996-

Smithburn et al., "A neurotropic virus isolated from the blood of a native of uganda," Am. J. Trop. Med. 20: 471-492,

EXAMINER DATE CONSIDERED: 11/12/04	1	,
------------------------------------	---	---

^{*} Examiner: (initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

6395-64907 182428.doc TMH:jfb 04/11/03 OPERATURILY PAURID Attorney Docket Number 6395-64907 **Application Number** 09/701,536 Filing Date November 19, 2000 SISCLOSURE STATEMENT BY APPLICANT **First Named Inventor** Chang Art Unit **Examiner Name** Not yet known U.S. PATENT DOCUMENTS Examiner's Cite No. Number Date Name Initials* (optional) NC 4,810,492 March 7, 1989 Fujita et al. 5,021,347 Yasui et al. June 4, 1991 Materdura et al. 5,229,293 July 20, 1993 Lai et al. Feb. 27, 1996 5,494,671 5,514,375 May 7, 1996 Paoletti et al. 6,074,865 June 13, 2000 Kelly et al. FOREIGN PATENT DOCUMENTS Examiner's Cite No. Number Date Country (optional) Initials* WQ 92/02548 WIPO May 20, 1991 (French w/English abstract) WO 93/06214 April 1, 1993 WIPO WQ 02/072036 Sept. 19, 2002 WIPO Oct. 24, 2002 WIPO WO 02/083903 JP 89025725 APAN May 1989 (English Abstract only) JP 53133627 November 1978 JAPAN (English Abstract only) JP 63004895 JAPAN (English Abstract only) JP 63105682 May 10, 1988 **JAPAN** (English Abstract only) JP 65000611 1965 **JAPAN** (English Abstract only) DATE **EXAMINER** SIGNATURE: CONSIDERED:

* Examiner:	Initial in	, f reference	considered,	whether or	not in	conform	ance wit	h MI	PEP 6	509.	Draw	line thro	ough cite	if not
in conform	ance and	i not consi	dered. Inclu	ide copy of	this fo	rm with i	next con	nnun	icatio	on to	applic	ant		

Halfarence were not considered. IDS Information Disclosure Statement (1449) Page 1 of 5 Barly to comply with 37 CPR 1.98.